Although the present study focused on scopolamine-induced cholinergic dysfunction as a model of cognitive impairment, it is important to note that the cholinergic hypothesis alone cannot fully account for the complexity of Alzheimer’s disease, which also involves amyloid deposition, tau pathology, oxidative stress, and neuroinflammation. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.